Inclusion Criteria:

•Male or female patients aged between 30 and 85 years of age
•Body mass index of 18 to 32 kg/m2, body weight of at least 50 kg.
•Diagnosis of idiopathic Parkinson's disease
•Patients must have provided written informed consent prior to performing any study procedures
•QTc interval of < 450ms (or QTc < 480ms in patients with Bundle Branch Block).


Exclusion Criteria:

•Patients who have an abnormality on physical examination.
•Patients who have medical conditions which could present a safety concern.
•Patients who have a clinically significant abnormal laboratory value, ECG, or physical examination finding
•Positive result for Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV) antibody
•Positive alcohol test result and / or urine test for undeclared drugs
•Recent history of moderate to severe dizziness, syncope, or orthostatic hypotension
•Significant sleep disorder or Epworth Sleep Score (Appendix 5) > 9
•Patients with a lying/sitting diastolic blood pressure =110mmHg or =50mmHg or a systolic blood pressure =180mmHg or =90mmHg
•History of any dopaminergic treatment (other than ropinirole IR and L-dopa) within 2 weeks prior to first dose.
•Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 or induce CYP1A2
•Patients who smoke >20 cigarettes per day and will not maintain a constant smoking habit for the duration of the study.
•Blood donation or significant blood loss less than 90 days before Day 1 of the current study.
•Definite or suspected personal history, or family history, of adverse reactions or hypersensitivity to ropinirole or to drugs with a similar chemical structure.
•Use of any investigational drug (with the exception of ropinirole PR/CR) within 30 days or 5 half lives (whichever is longer) before the start of dosing with study medication.
•Patients who have received over-the-counter (OTC) medicine within 48 h before the first dose of study drug.
•Recent history, or suspicion, of drug dependence or abuse of alcohol
•Significant concern, or likelihood, that the patient will drop out of the study prematurely, will require new or prohibited concomitant medications during the study period, or will not be compliant with study procedures.
•Women who are pregnant or breast-feeding.
•Female patient is currently either of:
a) Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or any female who is surgically sterilized (via documented hysterectomy or bilateral tubal ligation).
(For purposes of this study, postmenopausal is defined as one year without menses)
OR
b) child-bearing potential, has a negative urine/serum pregnancy test at the Screening Visit (prior to investigational product administration), and agrees to use acceptable contraception from one month prior to study Day 1 until one month after completion of the study (ie. one month after the follow-up visit). All hormonal birth control must have been administered for at least one monthly cycle prior to the Screening Visit. GSK acceptable contraception methods, when used consistently and in accordance with both the product label and the instructions of a physician, are as follows:
-) complete abstinence
-) sterilization of patient's male partner prior to female patient's entry into study
-) oral contraceptive (either combined or progestogen only)
-) any intra-uterine device with a documented failure rate of less than 1% per year
-) systemic contraception (eg. norplant system)
-) double barrier method if comprised of a spermicide with either a condom or diaphragm
•Patients with prior or current major psychosis

• Germany (click to view all sites in Germany)
• GSK Investigational Site
  Berlin, Berlin, 10117; Completed;
  
• South Africa (click to view all sites in South Africa)
• GSK Investigational Site
  George, Eastern Cape, 6529; Completed;